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ª 2011 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
In recent years series attention has been directed toward the
discovery and development of new antifungal drugs. Mostly
caused by Candida albicans, these infections are often spread
through the use of broad-spectrum of antibiotics agents, anti-cancer, and anti-AIDS drugs. The main problem in the treat-
ment of fungal infection is the increasing drug resistance
subjected to antimycotic therapy such as persons infected with
HIV (Wildfeuer et al., 1998). Azoles (imidazole and triazole)
are present in many effective antifungal drugs, widely used
for the treatment of topical or inner mycoses, in particular
AIDS-related mycotic pathologies (Koltin, 1990).
Their main effect is to block fungal ergosterol biosynthesis
by preventing the access of natural substrate lanosterol to the
active site of the cytochrome P-450-dependent enzyme 14a-
lanosterol demethylase (Odds, 2003). Since the identiﬁcation
of clotrimazole in 1972 (Buchel et al., 1972), a number of anti-
fungal imidazole agents have been studied and now are used in
clinical practice; that are miconazole and bifonazole (From-
tling, 1988). Mannich bases have gained importance due to
their application in antibacterial activity (Holla et al., 1998;
Sarangapani and Reddy, 1994) and other applications are in
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Krosche, 1912). Moreover N-bridged heterocyclic derivatives
show important antibacterial activity (Turan-Zitouni et al.,
2005). The aminoalkylation of aromatic substrates by the
Mannich reaction is of considerable importance for the
synthesis and modiﬁcation of biologically active compounds
(Tramontini and Angliolini, 1990). Mannich bases have several
biological activities such as antimicrobial (Edic-Saric et al.,
1980) and anticancer (Borensteinand Doukas, 1987). Morpho-
line derivatives were reported to possess antimicrobial (
Tramontini, 1973), anti-inﬂammatory (Thompson, 1968) and
central nervous system activities ( Cummings and Shelton,
1960). Therefore, bearing in mind the above observation, we
were led to synthesize and test the antimicrobial activity of a
new series of Mannich base derivatives.2. Experimental section
2.1. General procedures
Melting points were recorded in open capillary tubes and were
uncorrected. The IR spectra (KBr) were recorded on a Shima-
dzu 8201pc (4000–400 cm1). The 1H NMR and 13C NMR
were recorded on a Bruker DRX-400 MHz. Mass spectra
(EI) were recorded on a Jeol JMS D-300 spectrometer operat-
ing at 70 eV. The elemental analysis (C, H, N and S) was re-
corded using an Elementer analyzer model (Varian EL III).
The purity of the compounds was checked by thin layer chro-
matography (TLC).
2.1.1. 3-(Furan-2-yl)-3-(morpholin-4-yl)-N-phenylpropanamide
I
To prepare the mixture of furfuraldehyde (0.1 mol, 10.6 mL),
morpholine (0.1 mol, 8.7 mL) and phenylacetamide (0.1 mol,
13.5 g) in ethanol, the reaction mixture was reﬂuxed for 5 h.
The reaction mixture were cooled and poured into ice-cold
water. The precipitate was collected by ﬁltration. The precipi-
tate was dried and recrystallised from absolute ethanol. The
above procedure was followed by all the remaining compounds
III–VII.
IR (cm1): 3047 (CHstr in phenyl ring), 1680 (NHCO); 1H
NMR (DMSO-d6, 400 MHz): d 10.21 (s, 1H, CONH), 7.44–
7.19 (m, 5H, Ph-H), 6.44–6.47 (d, 2H in furyl ring), 7.60 (s,
1H, furyl ring), 4.30 (t, 1H, CH), 3.58 (t, 4H, CH2–O–CH2),
2.60 (t, 4H, CH2–N–CH2), 2.71 (d, 2H, COCH2).
13C NMR
(DMSO-d6, 400 MHz): d 176 (CONH), 110.3, 108.6, 144.9,
153.8 (furyl ring), 56.0 (N–CH), 37.3 (COCH2), 121.4, 129.4,
129.0, 137.9 (phenyl ring), 66.8 (CH2–O–CH2), 46.0 (CH2–
N–CH2). MS (EI): m/z (%) = 301.12 (M
++1, 12%),
224.25, 209.24, 167.32, 87.17.
2.1.2. 3-(Morpholin-4-yl)-N,3-diphenylpropanamide II
IR (cm1): 3022 (CHstr in phenyl ring), 1647 (NHCO); 1HNMR
(DMSO-d6, 400 MHz): d 10.29 (s, 1H, CONH), 7.67–7.22 (m,
5H, Ph-H), 7.39–7.24 (m, 5H, phenyl), 4.45 (t, 1H, CH), 3.45
(t, 4H, CH2–O–CH2), 2.89 (t, 4H, CH2–N–CH2), 2.64 (d, 2H,
COCH2).
13C NMR (DMSO-d6, 400 MHz): d 174.2 (CONH),
137.5, 122.3, 129.5, 128.0 (phenyl), 63.6 (N–CH), 38.5 (COCH2),
138.9, 129.3, 127.5, 126.9 (phenyl ring), 67.3 (CH2–O–CH2),
47.8 (CH2–N–CH2). MS (EI): m/z (%) = 311.45 (M
++1,
24%), 234.76, 158.20, 143.89, 116.90, 87.23.2.1.3. 3-(4-Chlorophenyl)-3-(morpholin-4-yl)-N-
phenylpropanamide III
IR (cm1): 3028 (CHstr in phenyl ring), 1648 (NHCO), 848
(C–Cl); 1H NMR (DMSO-d6, 400 MHz): d 10.64 (s, 1H,
CONH), 7.64–7.17 (m, 5H, Ph-H), 7.54–7.44 (d, 2H, phenyl),
4.25 (t, 1H, CH), 3.64 (t, 4H, CH2–O–CH2), 2.54 (t, 4H,
CH2–N–CH2), 2.64 (d, 2H, COCH2).
13C NMR (DMSO-d6,
400 MHz): d 177.2 (CONH), 134.7, 127.4, 127.9, 138.2 (phe-
nyl), 60.2 (N–CH), 38.3 (COCH2), 139.2, 122.4, 129.5, 127.0
(phenyl ring), 67.8 (CH2–O–CH2), 48.5 (CH2–N–CH2). MS
(EI): m/z (%) = 345.92 (M++1, 56%), 311.43, 235.76,
157.34, 144.20, 116.76, 86.09.
2.1.4. 3-(4-Hydroxyphenyl)-3-(morpholin-4-yl)-N-
phenylpropanamide IV
IR (cm1): 3032 (CHstr in phenyl ring), 1629 (NHCO), 1438
(C–OH); 1H NMR (DMSO-d6, 400 MHz): d 10.74 (s, 1H,
CONH), 9.49 (s,1H, Ph-OH), 7.66–7.21 (m, 5H, Ph-H),
7.15–6.78 (d, 4H, phenyl), 4.64 (t, 1H, CH), 3.74 (t, 4H,
CH2–O–CH2), 2.68 (t, 4H, CH2–N–CH2), 2.79 (d, 2H,
COCH2).
13C NMR (DMSO-d6, 400 MHz): d 174.6 (CONH),
154.2, 116.8, 129.7, 130.9 (phenyl ring), 63.8 (N–CH), 38.5
(COCH2), 135.4, 121.3, 127.2, 128.9 (phenyl ring), 65.4
(CH2–O–CH2), 48.9 (CH2–N–CH2). MS (EI): m/z
(%) = 311.45 (M++1, 34%), 234.76, 158.20, 143.89, 116.90,
87.23.
2.1.5. 3-(Morpholin-4-yl)-3-(4-nitrophenyl)-N-
phenylpropanamide V
IR (cm1): 3027 (CHstr in phenyl ring), 1617 (NHCO), 1527
(C–NO2);
1H NMR (DMSO-d6, 400 MHz): d 10.24 (s, 1H,
CONH), 7.60–7.15 (m, 5H, Ph-H), 8.26–7.47 (d, 4H, phenyl),
4.51 (t, 1H, CH), 3.65 (t, 4H, CH2–O–CH2), 2.48 (t, 4H,
CH2–N–CH2), 2.87 (d, 2H, COCH2).
13C NMR (DMSO-d6,
400 MHz): d 177.0 (CONH), 123.8, 124.9, 146.3, 145.9 (phenyl
ring), 64.4 (N–CH), 39.1 (COCH2), 120.8, 128.6, 127.9, 138.4
(phenyl ring), 67.1 (CH2–O–CH2), 48.0 (CH2–N–CH2). MS
(EI): m/z (%) = 356.76 (M++1, 76%), 311.34, 235.67,
159.01, 144.45, 114.63, 88.91.
2.1.6. 3-(4-Methoxyphenyl)-3-(morpholin-4-yl)-N-
phenylpropanamide VI
IR (cm1): 3042 (CHstr in phenyl ring), 1687 (NHCO); 1H
NMR (DMSO-d6, 400 MHz): d 10.44 (s, 1H, CONH), 7.59–
7.21 (m, 5H, Ph-H), 6.98–7.20 (d, 4H, phenyl), 4.20 (t, 1H,
CH), 3.54 (t, 4H, CH2–O–CH2), 3.80 (s, 3H, OCH3), 2.61 (t,
4H, CH2–N–CH2), 2.54 (d, 2H, COCH2).
13C NMR
(DMSO-d6, 400 MHz): d 176 (CONH), 131.1, 112.9, 148.3,
127.9 (phenyl ring), 61.6 (N–CH), 38.4 (COCH2), 121.7,
128.3, 128.1 (phenyl ring), 67.9 (CH2–O–CH2), 48.1 (CH2–
N–CH2), 40.9 (N(CH3)2). MS (EI): m/z (%) = 341.83
(M++1, 17%), 309.43, 234.67, 159.09, 142.94, 116.98, 88.46.
2.1.7. 3-(4-(Dimethylamino)phenyl)-3-morpholino-N-
phenylpropanamide VII
IR (cm1): 3081 (CHstr in phenyl ring), 1628 (NHCO); 1H
NMR (DMSO-d6, 400 MHz): d 10.98 (s, 1H, CONH), 7.69–
7.15 (m, 5H, Ph-H), 6.79–7.16 (d, 4H, phenyl), 4.67 (t, 1H,
CH), 3.74 (t, 4H, CH2–O–CH2), 3.12 (s, 6H, N(CH3)2)), 2.34
(t, 4H, CH2–N–CH2), 2.67 (d, 2H, COCH2).
13C NMR
(DMSO-d6, 400 MHz): d 176 (CONH), 131.1, 112.9, 148.3,
127.9 (phenyl ring), 61.6 (N–CH), 38.4 (COCH2), 121.7,
996 A. Idhayadhulla et al.128.3, 128.1 (phenyl ring), 67.9 (CH2–O–CH2), 48.1 (CH2–N–
CH2), 40.9 (N(CH3)2). MS (EI): m/z (%) = 355.93 (M
++1,
20%), 310.34, 235.85, 154.72, 140.92, 116.72, 86.92.
2.2. Biological evaluation
2.2.1. In vitro antibacterial screening
The compounds I–VII were evaluated for their in vitro antibac-
terial activity against Escherichia coli (MTCC-739), Proteus
mirabilis, Nonhemolytic streptococcus, Pseudomonas aeruginosa
(MTCC-2435), Micrococcus luteus (MTCC-106), Enterococcus
faecalis, Streptococcus epidermidis, Bacillus spp., Klebsiella
pneumoniae (recultured), and Staphylococcus aureus (MTCC-
96), by disc diffusion method (Bauer et al., 1966; Petersdorf
and Sherris, 1965). It was performed using a Mueller–Hinton
agar (Hi-Media) medium. Each compound and standard were
used at a concentration of 100 lg/mL in DMSO. The zone of
inhibition was measured after 24 h incubation at 37 C.
2.2.2. In vitro antifungal screening
The compounds I–VII were evaluated for their in vitro anti-
fungal activity such as Aspergillusniger, C. albicans, Microspo-
rum audouinii and Cryptococcus neoformans (recultured) using
a disc diffusion method (Gillespie, 1994; Collins, 1976; Verma
et al., 1998) with sabouraud’s dextrose agar (Hi-Media). Each+ +
O
N
H
HN
CH3
O
O
CHO
+ +
O
N
H
HN
CH3
O
CHO
R
Scheme 1 Scheme of the
Table 1 Physical characterization of compounds I–VII.
Compd. No. R m.p. m.w. Yield (%) M.
I – 79 300.35 91 C17
II –H 55 310.39 87 C19
III –Cl 80 344.83 91 C19
IV –OH 92 326.38 88 C19
V –NO2 88 355.38 96 C19
VI –OCH3 68 340.41 94 C20
VII –N(CH3)2 76 353.45 91 C21compound and standard were used at a concentration of
100 lg/mL in DMSO. The zone of inhibition (mm) was mea-
sured incubated at 37 C.
3. Results and discussion
3.1. Chemistry
The compounds I–VII were synthesized by Mannich base
method (Scheme 1), the method described in literature (Jamal
Abdul Nasser et al., 2009, 2008). Physicochemical data of the
compounds I–VII are given in Table 1. The formation of all the
compounds was conﬁrmed by recording the IR, 1H NMR, 13C
NMR and elemental analyses. The IR spectrum of compound
I showed absorption bands at 3047 and 1680 cm1 correspond-
ing to aromatic C–H str and NHCO groups, respectively. The
1H NMR spectra of compound I shows a singlet observed at d
10.21, 4.30 and 2.71 corresponding to CONH, –CH– and
CONH2 protons, respectively.
13C NMR spectrum of the com-
pound I shows peaks at d 176.0, 56.0 and 37.3 corresponding
to CONH, N–CH– and CONH2 carbons, respectively. Mass
spectra of compound I show the molecular ion peak m/z
301.12 (M++1, 12%), which is conﬁrmed by the molecular
mass of compound I.EtOH
O
N
NH
O
O
 I 
EtOH
O
N
NHOR
II-VII 
synthetic route I–VII.
F. Elemental analysis, calculated (found) (%)
C H N
H20N2O3 67.98(67.87) 6.71(6.70) 9.33(9.28)
H12N2O2 73.52(73.54) 7.14(7.10) 9.03(9.05)
H21ClN2O2 66.18(66.28) 6.14(6.10) 8.12(8.10)
H22N2O3 69.92(69.87) 6.79(6.69) 8.58(8.55)
H21N2O4 64.21(64.31) 5.96(5.84) 11.82((11.78)
H24N2O3 70.56(70.50) 7.11(7.09) 8.23(8.31)
H27N3O2 71.36(71.29) 7.70(7.65) 11.89(11.95)
Table 2 Antibacterial activity of compounds I–VII.
Test organisms Compound I Compound II Compound III Compound IV Compound V Compound VI Compound VII Ciproﬂoxacin
E. coli 6 8 9 – – – – 27
P. mirabilis 8 – – – – 12 – 19
Non streptococcus 5 – – 16 10 16 – 17
P. aeruginosa 9 – – 18 – – 10 20
M. luteus – 5 – – – – 12 32
E. faecalis 12 – – – 12 15 – 26
S. epridermidis – 6 20 – 14 – – 15
K. pneumoniae – – – – 18 – – 19
Bacillus spp. – – – – – 12 12 20
S. aureus 14 6 13 – 9 – 18 22
The compounds were used at concentration 100 lg/mL.
Ciproﬂoxacin used as the standard.
Zone of inhibition measured at (mm).
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3.2.1. Antibacterial activity
Compound III is highly active against S. epridermidis whereas
compound VI has equipotent activity against Non hemolytic
streptococcus, and compound V has equipotent activity against
K. pneumoniae compared with ciproﬂoxacin. The bacterial
zones of inhibition values are summarized in Table 2. Antibac-
terial activity variation of compounds I–VII is shown in Fig. 1.
3.2.2. Antifungal activity
Compound IV has equipotent activity against M. audouinii
whereas compound V has equipotent activity against C. albi-
cans compared with standard clotrimazole. The fungal zones
of inhibition values are summarized in Table 3. Antifungal
activity variation of compounds I–VII is shown in Fig. 2.Figure 1 Antibacterial activ
Table 3 Antifungal activity of compounds I–VII.
Test organisms Compound I Compound II Compound III Compoun
A. niger 7 – 10 –
C. albicans 8 8 6 6
C. neoformans – 7 5 8
M. audouinii – 9 6 25
The compounds were used at concentration 100 lg/mL.
Clotrimazole used as the standard.
Zone of inhibition measured at (mm).3.2.3. Structural–activity relationship
From the results of the antimicrobial activity of synthesized
Mannich base derivatives, the following structure–activity
relationships can be derived:
O
N
O
NH
O
1
2
Compound I ity of compounds I–VII.
d IV Compound V Compound VI Compound VII Clotrimazole
12 – – 22
25 8 6 24
10 6 13 25
6 – 12 26
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Figure 2 Antifungal activity of compounds I–VII.
998 A. Idhayadhulla et al.Compound I has morpholine N-substituted furyl ring and
the amide containing the compound I shows a low response with
all bacterial and fungal species compared with the standard.
N
O
NH
O
1
2
 Compound II 
In general, it was observed that most of the compounds2having substituted phenyl rings showed better antimicrobial
activity than those with non-substituted phenyl rings. Com-
pound II has phenyl(1) and amide groups(2), compound II
shows a low response with all bacterial and fungal species.
N
O
NH
O
Cl
1
2
Compound  III 
Compound III has chlorobenzene(1) and amide group(2),compound III shows a signiﬁcant antibacterial activity against
S. epridermidis compared with standard Ciproﬂoxacin. Phenyl
substituted rings having 4-Cl as the electron withdrawing
group have no signiﬁcance of activity in the fungal strain.
N
O
NH
O
HO
1
2
Compound  IV Compound IV has 4-OH substituted phenyl(1) and amide
groups(2), compound IV shows a very low activity against
the antibacterial strain compared with standard Ciproﬂoxacin
whereas 4-OH as an electron withdrawing group has an equi-
potent activity against M. audouinii compared with standard
Clotrimazole.
N
O
NH
O
O2N
1
2
Compound  V 
In compound V the presence of the electron donating 4-
NO2 group shows an equipotent activity against K. pneumo-
niae and equipotent activity against C. albicans compared with
the standard.
N
O
NH
O
H3 CO
1
Compound VI 
Compound VI has 4-OCH3 substituted phenyl ring(1) and
amide group(2), compound VI shows an equipotent activity
against Non hemolytic streptococcus and antibacterial and very
low activity against the antifungal strain compared with stan-
dard Ciproﬂoxacin.
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NH
O
(H3C)2N
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2
Compound  VII 
Compound VII has dimethylnitrobenzyl(1) and amide
group(2), compound VII shows low response with all bacterial
and fungal species but equipotent activity against S. epridermi-
dis compared with standard Ciproﬂoxacin.
4. Conclusion
A new series of Mannich base derivatives I–VII were synthe-
sized and screened for antimicrobial activity. Among these,
compound III has high antibacterial activity against S. epride-
rmidis compared with standard Ciproﬂoxacin, which can be
beneﬁcial for further studies. This synthesized compound
could be extended to analyse its various pharmacological
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